Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Speculating in Takeover Targets -- Ignore unavailable to you. Want to Upgrade?

To: richardred who wrote (3229)	11/20/2012 11:21:54 AM
From: richardred	Read Replies (1) \| Respond to of 7238

New speculative buy-Picked up some CYAN - Cyanotech Corp. Sales were up for the quarter ,but profits were down ,due to start up costs for expansion. I also like the fact insiders have been buying more stock with open market purchases.

To: richardred who wrote (3229)	11/21/2012 10:41:27 PM
From: richardred	1 Recommendation Respond to of 7238

I was just speaking about health oriented acquisitions. Tomorrow I won't be thinking health conscious at all. :-) HAPPY THANKGIVING TO ALL! BASF strikes lowball deal to buy fish oil firm Pronova reuters.com

To: richardred who wrote (3229)	4/29/2013 10:00:41 AM
From: richardred	Read Replies (1) \| Respond to of 7238

Bayer found a new target. Bayer Shells Out $1.1B to Buy Contraceptive Maker Conceptus By Matt Egan Published April 29, 2013 FOXBusiness In an effort to strengthen its contraceptive portfolio, German drug and chemical maker Bayer unveiled an all-cash deal on Monday to acquire birth-control maker Conceptus ( CPTS) for $1.1 billion. Under terms of the deal, Conceptus shareholders will receive $31 a share in cash, representing a 19.7% premium on its Friday close at $25.90. Mountain View, Calif.-based Conceptus is known for its Essure permanent birth control procedure, which was approved by the FDA in 2002. Conceptus generates annual revenue of about $140 million and employed 286 people as of the end of last year. "Bayer is committed to augmenting its organic growth with strategic bolt-on acquisitions. The acquisition of Conceptus represents an excellent fit for our health-care business -- specifically in the United States, the world's most important health care market," Bayer CEO Marijn Dekkers said in a statement. Bayer said it plans to launch a public tender offer to acquire all of Conceptus within the next 10 business days. The two companies said the transaction, which is subject to anti-trust approval in the U.S., is expected to close by the middle of 2013. “We believe that under Bayer's ownership, the Essure product will more rapidly become the standard of care in our established markets, and will benefit in new markets from Bayer's global presence,” said Conceptus CEO D. Keith Grossman. Bayer is headquartered in Leverkusen, Germany, and its health-care subgroup notched 2012 sales of nearly 19 billion euros. While shares of Bayer slumped more than 2% on the news, Conceptus saw its shares soar 19.77% to $31.02 in premarket trading on Monday, putting them on track to extend their 23% 2013 rally. foxbusiness.com